Repaglinide

• CAT Number: A000743
• CAS Number: 135062-02-1
• Molecular Formula: C27H36N2O4
• Molecular Weight: 452.59
• Purity: ≥95%
• Synonyms: 135062-02-1; Prandin; NovoNorm; GlucoNorm; AG-EE 623 ZW
• Target: Potassium Channel
• Solubility: >17mg/mL in DMSO
• Storage: -20°C
• IUPAC Name: 2-ethoxy-4-[2-[[(1S)-3-methyl-1-(2-piperidin-1-ylphenyl)butyl]amino]-2-oxoethyl]benzoic acid
• InChI: InChI=1S/C27H36N2O4/c1-4-33-25-17-20(12-13-22(25)27(31)32)18-26(30)28-23(16-19(2)3)21-10-6-7-11-24(21)29-14-8-5-9-15-29/h6-7,10-13,17,19,23H,4-5,8-9,14-16,18H2,1-3H3,(H,28,30)(H,31,32)/t23-/m0/s1
• InChIKey: FAEKWTJYAYMJKF-QHCPKHFHSA-N
• SMILES: CCOC1=C(C=CC(=C1)CC(=O)NC(CC(C)C)C2=CC=CC=C2N3CCCCC3)C(=O)O

Repaglinide is an oral medication used to treat type 2 diabetes by helping to control blood sugar levels. It works by stimulating the pancreas to release insulin, especially after meals, by inhibiting ATP-sensitive potassium channels in pancreatic beta cells. This rapid onset of insulin secretion helps manage postprandial (after meal) blood sugar spikes. Repaglinide is typically taken before meals and may be prescribed alone or in combination with other antidiabetic drugs. Common side effects include hypoglycemia and weight gain.